Ilyang announces positive results for ilaprazole in phase 3 study

Published: 2008-08-14 06:59:00

Updated: 2008-08-14 06:59:00

Ilyang Pharm announced on August 8 that it has completed a multinational Phase 3 clinical study for ilaprozole, a new proton pump inhibitor, in six South East Asian countries including Thailand, Malaysia and Singapore.

During the study, the efficacy and safety of ilaprozole 10 mg was superior ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK